GENFIT Logo

GENFIT

Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.

GNFT | PA

Overview

Corporate Details

ISIN(s):
FR0004163111 (+2 more)
LEI:
969500XPWN2DMZQA5X73
Country:
France
Address:
885 AVENUE EUGENE AVINEE, 59120 LOOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GENFIT is a late-stage biopharmaceutical company dedicated to discovering and developing therapeutic and diagnostic solutions for patients with rare and life-threatening liver diseases. With a scientific heritage spanning over two decades, the company has established a diversified pipeline focused on conditions with high unmet medical needs. GENFIT is a leader in developing treatments for Acute-on-Chronic Liver Failure (ACLF) and its complications, such as Hepatic Encephalopathy. The company's R&D portfolio also includes programs for Cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD). A key achievement is the successful development of elafibranor for Primary Biliary Cholangitis (PBC), which is now being commercialized by a partner. In addition to therapeutics, GENFIT has a diagnostic franchise focusing on metabolic liver diseases (MASH/NASH) and ammonia.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 07:45
Regulatory News Service
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une…
French 204.9 KB
2025-11-10 07:45
Regulatory News Service
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Rege…
English 223.5 KB
2025-11-10 07:30
Regulatory News Service
GENFIT présente de nouvelles données précliniques prometteuses sur NTZ/G1090N d…
French 315.9 KB
2025-11-10 07:30
Regulatory News Service
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment …
English 217.0 KB
2025-09-22 22:00
Interim Report
Attestation de la personne responsable associée au rapport d'activité et financ…
French 118.9 KB
2025-06-17 20:30
Post-Annual General Meeting Information
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025
French 140.4 KB
2025-06-17 20:30
Post-Annual General Meeting Information
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
English 140.0 KB
2025-05-22 22:10
Quarterly Report
GENFIT Reports First Quarter 2025 Financial Information
English 163.4 KB
2025-05-22 22:10
Earnings Release
GENFIT : Information financière du premier trimestre 2025
French 146.7 KB
2025-05-20 22:10
Regulatory News Service
GENFIT to receive a €26.5 million milestone payment following the approval of p…
English 143.6 KB
2025-05-20 22:10
Regulatory News Service
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l…
French 137.3 KB
2025-05-14 22:10
Environmental & Social Information
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year…
English 793.3 KB
2025-05-07 22:10
Pre-Annual General Meeting Information
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposi…
French 129.1 KB
2025-05-07 22:10
Pre-Annual General Meeting Information
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Prepa…
English 135.6 KB
2025-05-05 07:30
Environmental & Social Information
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025
French 228.8 KB

Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENFIT

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GENFIT via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-07-07 N/A Other Buy 5,300 19,488.10 EUR
2023-07-06 N/A Other Buy 1,100 4,048.00 EUR
2023-07-05 N/A Other Buy 10,000 37,061.00 EUR
2023-07-03 N/A Other Buy 5,300 18,769.95 EUR

Peer Companies

CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CervoMed Inc. Logo
Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.
United States of America
CRVO
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark
CESSA
CG Invites Co., Ltd. Logo
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
South Korea
083790
CG Oncology, Inc. Logo
Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
United States of America
CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
South Korea
261780
Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.
South Korea
052670

Talk to a Data Expert

Have a question? We'll get back to you promptly.